Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, RefluxEsophagitis, Peptic
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2038
- Registration Number
- NCT00251693
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Lipid-lowering therapy
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 400
- Registration Number
- NCT00251680
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 908
- Registration Number
- NCT00251745
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, PepticEsophagitis, Reflux
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2054
- Registration Number
- NCT00251719
Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia
Phase 3
Terminated
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Stable statin therapy
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 649
- Registration Number
- NCT00249899
Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 415
- Registration Number
- NCT00249912
Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2010-06-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 451
- Registration Number
- NCT00247390
Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT00246909
- Locations
- 🇺🇸
Altana Pharma/Nycomed, Milwaukee, Wisconsin, United States
TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal Tumour (TC-015-IN)
Phase 3
Completed
- Conditions
- Surgical Resection of Superficial Renal Tumour
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 170
- Registration Number
- NCT00241163
Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 275
- Registration Number
- NCT00237497
© Copyright 2025. All Rights Reserved by MedPath